Danaher Stock: Buy After a 36% Decline?
💡 Key Takeaway
Danaher's stock, down 36% from its peak, presents a compelling buying opportunity as its business recovers and its valuation sits well below historical norms.
What Happened to Danaher?
Danaher (DHR), a legendary life sciences conglomerate, has delivered an astounding 52,700% return for investors since its founding in 1969. However, the stock has faced significant headwinds over the past five years, currently trading 36% below its all-time high.
The company's struggles stem from a post-pandemic hangover. Its business, which includes diagnostics and biotech tools, boomed during COVID-19 due to testing and vaccine manufacturing demand. Once that surge normalized, revenue declined sharply.
Adding to the pressure, sales in China, a key market representing about 11% of revenue, have been soft for several years. This combination of factors led to years of declining sales, which soured investor sentiment on the stock.
Signs of a turnaround emerged in 2024, with revenue bottoming and beginning to grow again. The company then announced a major $9.9 billion cash acquisition of Masimo (MASI), a leader in pulse oximetry technology, in February.
Why This Matters for Investors
This matters because Danaher appears to be pivoting from a multi-year slump back to its growth trajectory. The acquisition of Masimo is a strategic move that complements Danaher's existing diagnostics business and adds over $1.5 billion in annual sales.
Financially, the deal is expected to add $530 million in EBITDA by 2027. Since it's a cash acquisition, it won't dilute existing shareholders. This incoming profit stream should boost Danaher's per-share financials.
The company's valuation has become much more attractive. Historically, Danaher traded at an average price-to-earnings (P/E) ratio of about 32. Today, it trades at just over 22 times this year's estimated earnings, representing a significant discount.
Danaher started its 2025 fiscal year strong, with Q1 non-GAAP earnings growing 9.5% year-over-year and beating expectations. Management forecasts over $5 billion in free cash flow this year, providing ample fuel for further growth or acquisitions.
Analysts project average annual earnings growth of 8-9% over the next several years. With a proven business system and a cheaper valuation, the stock's risk-reward profile has improved for long-term investors.
Source: The Motley Fool
Analysis generated by Bobby AI quantitative model, reviewed and edited by our research team. This is not financial advice. Always do your own research before making investment decisions.
Bobby Insight
Danaher stock is a buy for patient investors seeking a high-quality company at a discounted price.
The core business is recovering, a major accretive acquisition is underway, and the stock trades at a compelling valuation compared to its own history. While challenges in China persist, the company's proven Danaher Business System and strong cash generation provide a solid foundation for future growth.
What This Means for Me
